# Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
21/02/2006		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
29/03/2006	Completed	[X] Results		
<b>Last Edited</b> 08/11/2011	Condition category Circulatory System	[] Individual participant data		

#### Plain English summary of protocol

Not provided at time of registration

#### Contact information

#### Type(s)

Scientific

#### Contact name

Dr Narasimharajapura Rajendra

#### Contact details

Dept of Clinical Pharmacology Level 7 Ninewells Hospital Dundee United Kingdom DD1 9SY +44 (0)1382 496355

## Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

**Secondary identifying numbers** JUS002

# Study information

#### Scientific Title

#### **Study objectives**

Xanthine oxidase inhibition in chronic stable angina improves endothelial function.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approved by the Regional Ethics Committee on 08/11/2005, reference number: 05/S1401/101

#### Study design

Randomised double blind placebo-controlled crossover trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Not specified

#### Study type(s)

**Treatment** 

#### Participant information sheet

#### Health condition(s) or problem(s) studied

Chronic stable angina

#### Interventions

Allopurinol versus placebo

#### Intervention Type

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

Allopurinol

#### Primary outcome measure

Change in endothelial function as assessed by:

- 1. Flow-mediated dilatation
- 2. Forearm venous occlusion plethysmography

#### Secondary outcome measures

Changes in brain natriuretic peptide (BNP)

#### Overall study start date

05/01/2006

#### Completion date

02/04/2008

# **Eligibility**

#### Key inclusion criteria

- 1. Documented coronary artery disease
- 2. Chronic stable angina

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Sex

Both

#### Target number of participants

88

#### Key exclusion criteria

- 1. Left ventricular systolic dysfunction
- 2. Renal failure
- 3. Concomitant warfarin therapy
- 4. Allergy to allopurinol

#### Date of first enrolment

05/01/2006

#### Date of final enrolment

02/04/2008

### Locations

#### Countries of recruitment

Scotland

**United Kingdom** 

#### Study participating centre

#### **Dept of Clinical Pharmacology**

Dundee United Kingdom DD1 9SY

# Sponsor information

#### Organisation

University of Dundee (UK)

#### Sponsor details

The Nethergate
University of Dundee
Dundee
Scotland
United Kingdom
DD1 4HN

#### Sponsor type

University/education

#### **ROR**

https://ror.org/03h2bxq36

# Funder(s)

#### Funder type

Charity

#### Funder Name

The British Heart Foundation (UK)

# **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration

# Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	16/08/2011		Yes	No